Genmab — Marts 2023
-
Morn, Stærkt signal som støtter casen op til q1 regnskab 10 maj og Epcoritamab PDUFA 21 maj. Derefter ASCO konferencen 2023 2-6 juni. Kommer vel også snart H2H data mod Darzalex. https://www.proinvestor.com/boards/111617/$/111666
-
-
-
-
BioNTech Announces Fourth Quarter and Full Year 2022 Financial Results and Corporate Update https://investors.biontech.de/news-releases/news-release-details/biontech-announces-fourth-quarter-and-full-year-2022-financial
-
BioNTech Fourth Quarter and Full Year 2022 Earnings Presentation https://investors.biontech.de/events/event-details/2022-q4-and-full-year-earnings-call
-
-
Transactions in connection with share buy-back program https://www.proinvestor.com/investornyt/960086/transactions-in-connection-with-share-buy-back-program
-
Jeg spurgte chatgpt om bnt322. Tror ikke den er helt gal på den : The two companies plan to use Biontech's innovative mRNA technology platform to develop a new class of antibody therapeutics targeting solid tumors. BNT322 is designed to selectively destroy cancer cells by engaging the immune system in a highly specific manner
-
Genmab Announces Appointment of Martine van Vugt to Chief Strategy Officer https://ir.genmab.com/news-releases/news-release-details/genmab-announces-appointment-martine-van-vugt-chief-strategy
-
The M&A hunt is on — here are the prime targets
Companies with advanced molecular therapies, oncology assets and obesity treatments could be fuel for a dealmaking fire this year.
PharmaVoice (www.pharmavoice.com)
-
Tror ikke lige Amanda er så heldig med den "liste" over opkøbs kandidater. Altimmune har lige præsenteret data. Fint vægtab på ca 10%. Men "Most patients experienced nausea and vomiting of mild and moderate severity"
-
Ja, AbbVie (ABBV) står over for et af de stejleste patentfrafald i branchen, når Humira mister sin amerikanske eksklusivitet næste år. Analytikere forventer, at virksomheden vil have 69 milliarder dollars i frit cash flow frem til 2024 for at genopbygge sine hylder. Andre firmaer, der forventes at se høje kontanter, er Roche, Bristol Myers og Merck.
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind